Pharma Manufacturing

Chinese CDMO WuXi Biologics is selling its vaccine manufacturing facility in Dundalk, Ireland, for approximately $500 million to Merck. #CDMO #vaccinemanufacturing #manufacturingfacility #Merck #WuXiBiologics #MSD #pharmanews #pharmamanufacturing https://lnkd.in/dZRgkfUE

Novo Holdings has joined a $92.8 million (€90 million) Series A financing round for Orbis Medicines to support the development of its nGen platform, which integrates automated chemistry and machine learning to manufacture oral macrocycle drugs. The technologies aim to overcome manufacturing challenges in producing oral alternatives to blockbuster biologic drugs. #NovoHoldings #OrbisMedicines #machinelearning #automatedchemistry #macrocycledrugs #manufacturingchallenges #biologic #pharmanews #pharmamanufacturing https://lnkd.in/dxzHvxUi

The FDA has issued final guidance for its Advanced Manufacturing Technologies (AMT) Designation Program, a framework aimed at encouraging the use of innovative manufacturing approaches in drug production. #FDA #AMT #AdvancedManufacturingTechnologiesDesignationProgram #manufacturing #manufacturingapproaches #pharmanews #pharmamanufacturing https://lnkd.in/eG_AvzBu

Lifecore Biomedical announced financial results for the second quarter of fiscal 2025 with revenues of $32.6 million, an 8% increase compared to the prior year period, driven by higher sales from its largest CDMO customer. #LifecoreBiomedical #CDMO #financialresults #pharmanews #pharmamanufacturing https://lnkd.in/eYJvDEdr

See what you may have missed this week in Pharma with this edition of Editor's (re)View, where our editors handpick notable happenings in the industry worthy of extra attention. This week, Greg Slabodkin discusses the Chinese government's reveal of plans to accelerate the development of biomanufacturing in 2025.  Be sure to read more using the link below. #biomanufacturing #Editorsreview #PharmaManufacturing #pharmanews #biotechnology #Chinesebiomanufacturing https://lnkd.in/dRWDyV-V

Biologics CDMO Avid Bioservices announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to its pending $1.1 billion acquisition by GHO Capital Partners and Ampersand Capital Partners. GHO Capital Partners LLP, Ampersand Capital Partners #AvidBioservices #GHOCapitalPartners #AmpersandCapitalPartners #biologics #CDMO #pharmanews #pharmamanufacturing https://lnkd.in/gauGgf5d

Innovent Biologics and Roche have entered into an exclusive global license agreement to advance IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC) for the treatment of small cell lung cancer. #InnoventBiologics #Roche #globallicenseagreement #antibodydrugconjugate #ADC #smallcelllungcancer #pharmanews #pharmamanufacturing https://lnkd.in/gMFW6P8B

Vincerx Pharma announced a proposed merger with privately held antibody-drug conjugate (ADC) company Oqory Inc., whose lead candidate — OQY-3258 — is being evaluated in two Phase 3 studies. #VincerxPharma #Oqory #ADC #mergers #pharmanews #pharmamanufacturing https://lnkd.in/gATxT68h

Chinese biomanufacturing is poised for “significant” growth next year, according to an announcement from China’s Ministry of Industry and Information Technology. #biomanufacturing #China #Chinesebiomanufacturing #ChinasMinistryofIndustryandInformationTechnology #manufacturing #pharmanews #pharmamanufacturing https://lnkd.in/gTt4czqX

Be sure to read this Editors' (re)View, where our editors discuss pharma happenings. See what you may have missed. This week, Greg Slabodkin explores WuXi AppTec’s announcement that it has agreed to sell WuXi Advanced Therapies, its cell and gene therapy unit, to New York-headquartered private equity firm Altaris. Altaris, LLC #EditorsReview #WuXiAppTec #WuXiAdvancedTherapies #Altaris #pharmanews #pharmamanufacturing #pharmaindustry #genetherapy #privateequityfirm https://lnkd.in/gMCccBKS